Roxane Laboratories: A Connection to Excellence for Your Patients and for Patients Everywhere who Rely on Our Products

Published Online: Tuesday, July 23, 2013

Behind every Roxane product, you’ll find a team that connects you to the people who work tirelessly to bring economical generic pharmaceuticals to patients everywhere. With continual advances in cutting-edge administration and dosage for more than 100 medications, and ongoing efforts to keep our product line affordable and available to as many customers as possible, the team at Roxane Laboratories is laser focused on meeting and exceeding the needs of each and every one of our customers and patients.

Roxane Laboratories operates as the research and development and sales and marketing arms of Boehringer Ingelheim’s multisource pharmaceutical business. Today, Roxane markets more than 100 medications in 300 package sizes.

We are committed to expanding our line of multisource pharmaceutical products that are formatted as bulk and unit-dose package configurations for liquids and solids; coated, sustained-release and controlled-release tablets; nasal sprays; topical solutions; cytotoxics; and CII narcotics.

Advancements in controlled substances, sustained-release items, potent compounds, unit doses and bulk packaging all reflect our dedication to provide customers with innovative, technically complex products from our FDA-approved facilities.

The team at Roxane understands how every aspect of our business can affect your patients’ lives—everything from answered phone calls to correct shipments and efficient manufacturing processes. We strive for excellence with every customer experience and are committed to providing quality products for a range of clinical areas.

Roxane also recognizes that growth and development in our product lines impact patients everywhere; our team contains highly skilled researchers who are constantly working to expand the number of our generic pharmaceuticals. These scientists, combined with our patent-experienced attorneys and purchasing team, are tasked with putting more affordable generic treatments on the market and into your hands—as soon as possible.

Our award-winning pursuit of high-quality products and service is also accompanied by a lean manufacturing model staffed by a skilled, flexible workforce. This innovative manufacturing and business practice allows for quick shifts in production based on marketing opportunities and business needs. As always, Roxane maintains impressive levels of safety, quality, and compliance.

To meet the changing needs of our patients, Roxane has continued to grow its product lines to offer a variety of treatment options. To accommodate this growth, we expanded our Wilson Road facility in central Ohio by adding a 105,000-square-foot complex in 2011. Like all of our efficient operations, this facility meets the rigorous design standards required for safe and compliant manufacturing.

Quality, safe and affordable growth has continued for Roxane in 2012. We are proud to have launched these 11 new generic products:
  • Dipyridamole Tablets, USP
  • Quetiapine Fumarate Tablets
  • Tinidazole Tablets
  • Hydromorphone Hydrochloride Oral Solution, USP
  • Nevirapine Tablets
  • Nevirapine Oral Suspension
  • Montelukast Sodium Tablets
  • Montelukast Sodium Chewable Tablets
  • Oxcarbazepine Oral Suspension
  • Irbesartan and Hydrochlorothiazide Tablets, USP
  • Irebesartan Tablets, USP

Key Executives:
  • Randy Wilson, General Manager
  • Paul Kersten, RPh, Vice President Sales and Marketing
  • Mark Boudreau, Executive Director of Sales
  • Michael Plessinger, Director of Marketing
Roxane. Right NowTM

Visit to view our complete product catalog and reach our TouchPoint Customer Service Center 24/7 for information about your account and other status. 

Latest Articles
Skipping a flu shot may put patients at greater risk for flu-related pneumonia.
This weekly video program highlights the latest in pharmacy news, product news, and more.
Mylan has launched a generic version of Teva Pharmaceuticals’ Adderall in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 20 mg, and 30 mg doses.
The FDA has approved Boehringer Ingelheim’s oral direct thrombin inhibitor dabigatran etexilate mesylate (Pradaxa) for the prophylaxis of deep vein thrombosis and pulmonary embolism in patients who have had hip replacement surgery.
Latest Issues